Journal: Cell Reports Medicine

Article Title: Boosting NAD preferentially blunts Th17 inflammation via arginine biosynthesis and redox control in healthy and psoriasis subjects

doi: 10.1016/j.xcrm.2023.101157

Figure Lengend Snippet: The CD4 + T cell immunomodulatory effect of NR is dependent on cellular NAD + levels (A) IL-17 release in response to Compound 78c (78c) to inhibit CD38 or rucaparib (Ruc) to inhibit PARPs (n = 8) in CD4 + T cells. (B and C) Cellular ROS (B) and mitochondrial ROS (C) following 78c or Ruc (n = 4). (D) IL-17 release following 78c or Ruc in Th17 cells (n = 8). (E and F) Cellular ROS (E) and mitochondrial ROS (F) following 78c or Ruc in Th17 cells (n = 4). (G) IL-17 release in cd38 - or sarm1 -KD CD4 + T cells (n = 8). (H and I) ROS (H) and mitochondrial ROS (I) in cd38 - or sarm1 -KD cells (n = 4). (J) IL-17 release in cd38 - or sarm1 -KD Th17 cells (n = 4–8). (K and L) Cellular ROS (K) and mitochondrial ROS (L) in cd38 - or sarm1 -KD Th17 cells (n = 4). (M and N) Protein expression of Nrf2 and Sqstm1 in cd38 -KD CD4 + T cells (N, n = 8) and sarm1 -KD cells (N, n = 4–6). The p values for comparisons of two groups calculated using paired two-tailed Student’s t test, or one-way ANOVA when comparing more than two groups (vehicle vs. treated or NC vs. CD38-KD/SARM1-KD). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Histograms represent mean ±SEM.

Article Snippet: Compound 78c , Selleckchem , Cat. S8960.

Techniques: Expressing, Two Tailed Test

Journal: Cell Reports Medicine

Article Title: Boosting NAD preferentially blunts Th17 inflammation via arginine biosynthesis and redox control in healthy and psoriasis subjects

doi: 10.1016/j.xcrm.2023.101157

Figure Lengend Snippet:

Article Snippet: Compound 78c , Selleckchem , Cat. S8960.

Techniques: Flow Cytometry, Virus, Recombinant, Staining, Cell Stimulation, CyQUANT Assay, Proliferation Assay, Bicinchoninic Acid Protein Assay, In Vitro, Antioxidant Assay, Detection Assay, GSH Assay, Bioassay, Transcription Factor Assay, Extraction, Enzyme-linked Immunosorbent Assay, Control, Software, Cell Isolation, Transfection

Journal: Translational Oncology

Article Title: CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer

doi: 10.1016/j.tranon.2025.102414

Figure Lengend Snippet: Evaluating CD38’s impact on cell infiltration and communication in ovarian cancer by single-cell resolution (A) Cell type annotation for six datasets categorized by major lineage. The heatmap showed the average gene expression of CD38 in different populations of malignant, immune and stromal cells. (B) UMAP dimensionality reduction of cellular landscape of ovarian cancer and CD38 expression across different cell populations. (C) Violin plots illustrated the distribution of CD38 expression levels among various cell populations in normal and ovarian cancer tissues. (D) Violin plots illustrated CD38 expression patterns among cell populations in primary, metastatic, and relapsed ovarian cancer tissues. (E) Heatmap showed the intensity of intercellular communication in the GSE118828 dataset. (F) Comparison of gene expression levels involved in cell-cell interactions between high and low CD38-expressing groups in the GSE9891 dataset (* p < 0.05, ** p < 0.01, **** p < 0.0001). (G) qPCR analysis of relative mRNA expression of cell-cell interaction genes in subcutaneous tumors from C57BL/6 mice treated with Compound 78c, normalized to β-actin ( n = 3 per group, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

Article Snippet: Four weeks post-inoculation, the CD38-specific inhibitor Compound 78c (S8906, Selleck Chemicals, TX, USA) was administered to C57BL/6 by intraperitoneal injection (10 mg/kg/dose [ ]) every two days over a period of 3 weeks.

Techniques: Gene Expression, Expressing, Comparison

Journal: Translational Oncology

Article Title: CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer

doi: 10.1016/j.tranon.2025.102414

Figure Lengend Snippet: CD38 promotes ovarian cancer proliferation, metastasis and immune cell infiltration in vivo (A) Tumor formation in C57BL/6 mice ubcutaneously injected with ID8 cells stably expressing vector or CD38 (ID8-Vector or ID8-OVE-CD38). After 6 weeks, tumors were excised and photographed. (B) Quantification of tumor volume and total tumor weight in the transplanted tumors ( n = 7 for ID8-Vector, n = 5 for ID8-OVE-CD38, *p<0.05, *** p < 0.001). (C) Flow cytometry detected T cell proportion in the transplanted tumors ( n = 3 per group, * p < 0.05). (D) Abdominal metastases in BALB/c nude mice intraperitoneally injected with SKOV3 cells stably expressing vector or CD38 (SKOV3-Vector or SKOV3-OVE-CD38). After 4 weeks, tumors were excised and photographed. Upper panels: peritoneal metastasis nodules. Lower panels: mesenteric metastasis nodules. (E) Quantification of peritoneal metastasis nodules counts and total tumor weight, n = 7 for SKOV3-Vector, n = 6 for SKOV3-OVE-CD38, * p < 0.05, ** p < 0.01). The proportion of mesenteric metastases nodules was evaluated using Fisher's exact test (* p < 0.05). (F) Tumor formation in C57BL/6 mice subcutaneously injected with ID8 cells. After 4 weeks, Compound 78c were administered intraperitoneally (10 mg/kg/dose) every two days for 3 weeks. Tumors were excised and photographed. (G) Quantification of tumor volume in the transplanted tumors ( n = 5 per group, * p < 0.05, ** p < 0.01). (H) Flow cytometry detected proportion of CD38-positive TCs and TILs, CD4/8 + T cells, macrophages, and PD-L1-positive cells in the transplanted tumors ( n = 3 per group, * p < 0.05, ** p < 0.01).

Article Snippet: Four weeks post-inoculation, the CD38-specific inhibitor Compound 78c (S8906, Selleck Chemicals, TX, USA) was administered to C57BL/6 by intraperitoneal injection (10 mg/kg/dose [ ]) every two days over a period of 3 weeks.

Techniques: In Vivo, Injection, Stable Transfection, Expressing, Plasmid Preparation, Flow Cytometry

Journal: Translational Oncology

Article Title: CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer

doi: 10.1016/j.tranon.2025.102414

Figure Lengend Snippet: CD38 promotes ovarian cancer tumorigenesis through PI3K-AKT and IL-6 pathway (A) KEGG enrichment plot of CD38 involvement in JAK-STAT and PI3K-AKT pathways. (B) qPCR analysis of relative core gene mRNA expression in the PI3K-AKT pathway in A2780 cells stably expressing vector or CD38 (Vector or OVE-CD38), normalized to β-actin ( n = 3 per group, *** p < 0.001, **** p < 0.0001). (C) qPCR analysis of relative CD38 and core gene mRNA expression in the PI3K-AKT pathway in subcutaneous tumors from C57BL/6 mice treated with Compound 78c, normalized to β-actin ( n = 3 per group, * p < 0.05, ** p < 0.01, **** p < 0.0001). (D) Western blot analysis of core protein expression levels in the PI3K-AKT pathway in A2780 cells stably expressing vector or CD38 (Vector or OVE-CD38), and CAOV3 cell lines stably expressing shNC or shCD38 (shNC or shCD38). (E) Luminex liquid suspension chip assay for 27 chemokines levels in SKOV3-Vector or SKOV3-OVE-CD38 mouse subcutaneous tumor tissues. (F) qPCR analysis of relative core gene mRNA expression in the IL6 pathway in subcutaneous tumors from C57BL/6 mice treated with Compound 78c, normalized to β-actin ( n = 3 per group, * p < 0.05, ** p < 0.01, **** p < 0.0001). (G) Comparative expression analysis of IL6 pathway core genes between high and low CD38-expressing groups in the GSE9891 dataset (*** p < 0.001, **** p < 0.0001).

Article Snippet: Four weeks post-inoculation, the CD38-specific inhibitor Compound 78c (S8906, Selleck Chemicals, TX, USA) was administered to C57BL/6 by intraperitoneal injection (10 mg/kg/dose [ ]) every two days over a period of 3 weeks.

Techniques: Expressing, Stable Transfection, Plasmid Preparation, Western Blot, Luminex, Suspension